PFE · News · 20261114N

GLP-1 China Reimbursement Access

PFIZER INC · 2026-11-14 · Importance 44 · Surprise 42 · In source text

China added GLP-1 drugs from Pfizer and Innovent Biologics to its national health insurance scheme for type 2 diabetes patients, effective January 1. The inclusion expands access to China’s diabetic population and places the drugs in a reimbursement environment where inclusion typically leads to lower manufacturer prices. The change also intensifies competition with Novo Nordisk’s Ozempic, which is already on the list.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
revenuepositiveprobable—China added Pfizer's GLP-1 drugs to its national health insurance scheme for type 2 diabetes patients, effective January 1.